Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis.

S. Rafiei,K. Tiedemann,Sébastien Tabariès,P. Siegel,S. Komarova

DOI: https://doi.org/10.1016/j.canlet.2015.03.012

IF: 9.756

2015-06-01

Cancer Letters

Abstract:

What problem does this paper attempt to address?

Global research landscape on antiphospholipid syndrome and systemic lupus erythematosus: Trends, collaborations, and future directions

Heng Bai,Jie Tian

DOI: https://doi.org/10.1016/j.autrev.2024.103696

IF: 17.39

2024-11-24

Autoimmunity Reviews

Abstract:Background Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are frequently studied together due to their close relationship. Despite significant research in this area, bibliometric studies addressing global research trends, key hotspots, and developmental trajectories are still lacking. Methods This study employs bibliometric analysis to examine 2233 publications on APS and SLE from 1989 to 2024, sourced from the Web of Science (WOS) database. Visualization tools, such as the bibliometrix R package, CiteSpace, and VOSviewer, were utilized. Results The analysis includes contributions from 9322 researchers across 2534 institutions in 91 countries, with publications spread across 585 journals. Research activity has increased substantially since 2015, reflecting the growing academic interest in the field. The United States led in publication volume, while Tel Aviv University produced the highest number of publications. Lupus had the highest number of both publications and citations. Yehuda Shoenfeld is the most prolific author, while Ronald A. Asherson is the most co-cited author. Keyword analysis revealed five major themes in APS and SLE research, covering thrombosis, cardiovascular diseases, immune response, pregnancy complications, and other connective tissue diseases. Thematic map emphasized the need for future research to focus on the immune mechanisms of antiphospholipid antibodies, thrombosis management, management of pregnancy complications, and interventions for neuropsychiatric symptoms. Conclusion This study analyzes the literature on APS and SLE, revealing trends in the research of their immune mechanisms, thrombosis management, pregnancy complications, and neuropsychiatric symptoms, and providing strong guidance for future research directions.

immunology
Research Progress on the Relationship between Anticardiolipin Antibodies and Adverse Pregnancy Outcomes

Qi WU,Dan-qing CHEN

DOI: https://doi.org/10.3969/j.issn.1674-1870.2017.06.004

2017-01-01

Abstract:Antiphospholipid antibodies are a group of antibodies with specificity for binding to negatively charged phospholipids on the cell surface, including anticardiolipin antibodies, lupus coagulation inhibitor and anti-beta 2-glycoprotein I antibodies. They can cause a series of characteristic clinical symptoms, which are referred to as antiphospholipid syndrome. There is an international consensus on the classification criteria for definite antiphospholipid syndrome. Numerous studies have shown that anticardiolipin antibodies are associated with several adverse pregnancy outcomes, such as infertility, abortion, stillbirth, preeclampsia, placental insufficiency and so on. But its pathogenic mechanism is not yet clear. However, some investigators believe that anticardiolipin antibodies are not the main cause of adverse pregnancy outcomes. This paper focuses on the association between anticardiolipin antibodies and adverse pregnancy outcomes. And it also suggests investigators to optimize the experimental design and diagnostic criteria for classification, hopes to obtain more authoritative results using to guide clinical practice.
Antiphospholipid Syndrome: a Survey of Clinical Characters in Ten Cases

Chen Li-hua,Jiang Ling-ling,Li You-ming,Peng Qing-bi

DOI: https://doi.org/10.1631/jzus.2003.0616

2003-01-01

Abstract:Objective: To gain further understanding of the antiphospholipid syndrome (APS). Methods: Analysing clinical and laboratory data on ten cases of APS. Results: Thrombocytopenia appeared in all cases. Venous thrombi of limbs appeared in five cases and neurological abnormalities in two cases. Renal impairments were found in three cases. One case manifested left renal venous thrombi and the other two cases thrombotic microangiopathy. Budd-Chiari syndrome was found in one case. One of the ten cases was catastrophic APS (CAPS) presented as acute diffuse swelling, cyanosis, pain, ischemia and necrosis in fingers and limbs, recurrent shock, ascites, hepatic and respiratory dysfunction. Anticoagulants and corticosteroids could be effective foctive for dealing with APS. It was critical to treat catastrophic APS with anticoagulants or plasmapheresis as early as possible. Conclusion: APS shows variable manifestations for good prognosis, but catastrophic APS has fatal risk. The main treatment for APS is the use of anticoagulants and immunosuppressives.
Hughes syndrome: The discovery of the antiphospholipid syndrome

Munther Khamashta,Graham R V Hughes

DOI: https://doi.org/10.1016/j.medcli.2024.04.004

Abstract:In the 40 years since the original detailed description of antiphospholipid syndrome (APS), the condition has come to be regarded as one of the most common autoimmune diseases. The impact of the description has been enormous - for example, the recognition that some individuals with connective tissue diseases require anticoagulation rather than corticosteroids or anti-inflammatory treatment has bought about fundamental change in medical practice. In obstetrics, APS is now regarded as the most important prothrombotic cause of recurrent pregnancy loss - with pregnancy success improving from below 20% to current live birth rate over 80%. In neurology, APS may be associated with up to 20% of strokes in people under 40 - a striking figure not least in terms of medical economics, let alone in potentially preventable suffering. In vascular medicine, APS links immunology with thrombosis and vascular disease and may well provide insights into immunological factors in the pathogenesis of atherosclerosis.
Clinical analysis of the outcome in pregnant patients with Antiphospholipid syndrome

杨京晶,梁梅英,王山米,张冲

DOI: https://doi.org/10.13390/j.issn.1672-1861.2014.01.012

2014-01-01

Abstract:Objective Characteristics of diagnosis and treatment for pregnancy with antiphospholipid syndrome were discussed.Methods The medical records of pregnant women with antiphospholipid syndrome were retrospectively collected between January 1990 and July 2013.Results Thirteen women with APS were included. Twelve of them were primary APS,one was secondary APS.Ten of these patients were diagnosed as APS before pregnancy,three of them were diagnosed during pregnancy.Eight patients had experienced frequent spontaneous abortions(61.54%).None of them had perinatal death.Among the pregnancies,eleven had term births preterm births(84.62%),two had preterm births(15.38%),Two had intrauterine growth retardation(15.38%).Treatment included low-dose aspirin(2 cases),low molecular heparin(3cases),low-dose aspirin and prednisone(3 cases),low molecular heparin and aspirin(3 cases),corticosteroid and gamma globulin(1 case)and gamma globulin alone(1 case).All of the patients were prescribed with oral low-dose aspirin or low molecular heparin after birth until six weeks postpartum.Conclusions Appropriate therapy can improve the pregnancy outcome of antiphospholipid syndrome patients.The diagnosis and relevent treatment deserve more value for patients without the medical history of antiphospholipid syndrome before pregnancy.
Nitroalcohol Induced Hydrogel Formation in Amine-Functionalized Polymers.

Marissa R. Solomon,Naphtali A O'Connor,D. Paik,N. Turro

DOI: https://doi.org/10.1002/APP.31944

IF: 3

2010-07-15

Journal of Applied Polymer Science

Abstract:Certain β-nitroalcohols degrade under basic conditions or upon heating to form formaldehyde. This reaction provides an elegant approach to generate formaldehyde within a system at a desired time using the stimulus of pH or temperature. Using β-nitroalcohols as a delivery agent for formaldehyde, polymer crosslinking can be induced via stimulus. Such an approach is akin to those used to prepare "self-healing" polymers, which have received much attention recently. Herein, we describe the use of certain β-nitroalcohols as a masked formaldehyde delivery system and demonstrate its use as a crosslinking agent of amine functionalized polymers to form hydrogels. We examine the temperature and pH dependence of 2-nitro-1,3-propanediol and 2-(hydroxymethyl)-2-nitro-1,2-propanediol on the rate and extent of gelation and characterize the resulting gel by swelling and FTIR experiments.
Bibliometric analysis of global literature productivity in systemic lupus erythematosus from 2013 to 2022

Xintong Xie,Hao Yu,Youxian He,Mengxiang Li,Feng Yin,Xue Zhang,Qiuyu Yang,Guangliang Wei,Huidong Chen,Chengsong He,Yue He,Jie Chen,Xie, Xintong,Yu, Hao,He, Youxian,Li, Mengxiang,Yin, Feng,Zhang, Xue,Yang, Qiuyu,Wei, Guangliang,Chen, Huidong,He, Chengsong,He, Yue,Chen, Jie

DOI: https://doi.org/10.1007/s10067-023-06728-z

2023-09-06

Clinical Rheumatology

Abstract:Bibliometric analysis is a mature method for quantitative evaluation of academic productivity. In view of the rapid development of research in the field of systemic lupus erythematosus (SLE) in the past decade, we used bibliometric methods to comprehensively analyze the literature in the field of SLE from 2013 to 2022.

rheumatology
[Research Hotspots on Systemic Lupus Erythematosus in Pregnancy Based on Bibliometrics].

Shu-Ming Shao,Yi-Min Zhang,Xiao-Rui Zhang,Jie Liu,Chao-Mei Zeng,Jiong Qin

DOI: https://doi.org/10.3881/j.issn.1000-503x.15955

2024-01-01

Abstract:Objective To explore the research hotspots on systemic lupus erythematosus (SLE) in pregnancy based on the bibliometric analysis of the related articles published from 2018 to 2023 and provide directions for the future research in this field. Methods PubMed,Web of Science,and Embase were searched for the articles on SLE in pregnancy that were published from January 1,2018 to December 31,2023.VOSviewer was used to visualize the high-frequency keywords in the selected articles. Results A total of 266 articles were selected,from which 25 high-frequency keywords were extracted.The bibliometric analysis showed that the available studies about SLE in pregnancy mainly focused on maternal complications,maternal and fetal outcomes,and medications.The studies were limited regarding the predictors,autoimmunity,immunotherapy,and long-term outcomes of offspring. Conclusion Maternal complications,maternal and fetal outcomes,and medications are currently hotspots in the research on SLE in pregnancy,while predictors,autoimmunity,immunotherapy,and long-term outcomes of offspring may become future research directions.
A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction

Jing-Hui Wang,Guan-Rui Pan,Long Jiang

DOI: https://doi.org/10.3389/fimmu.2024.1493250

IF: 7.3

2024-11-24

Frontiers in Immunology

Abstract:Introduction: An increasing number of studies have demonstrated that immunotherapy may play a significant role in treating Atherosclerosis and has emerged as a promising therapy in this field. The aim of this study is to provide a comprehensive perspective through bibliometric analysis and investigate the existing hotspots and frontiers. Methods: This study searched records from Web of Science, PubMed, and Scopus from January 1, 1999, to May 27, 2023. By using bibliometric software CiteSpace (6.3.R1) and VOSviewer (1.6.19), co-occurrence analysis was used to count the frequency of co-occurrence of certain elements (e.g., countries, regions, institutions, etc.), cluster analysis was used to classify keywords, and burst analysis was used to identify research trends and hotspots. Results: The results showed that the number of annual publications has grown in a fluctuating manner; the USA, China, and the Netherlands have the highest numbers of publications, and the top three institutions are located in the Netherlands, Sweden, and the USA. In addition, Nilsson J published the highest number of papers; Ridker PM and his article "Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease" have played prominent roles. The top four Journals with the highest numbers of publications are "Arteriosclerosis Thrombosis and Vascular Biology", "Frontiers in Cardiovascular Medicine", "Circulation" and "Vaccine". In addition, keyword analysis indicates that inflammation, nanoparticles, adverse events associated with immune checkpoint inhibitors, T cells and tumor necrosis factor will be future research hotspots. Discussion: This study provides a comprehensive bibliometric analysis of immunotherapy in atherosclerosis, offering insights that advance scientific understanding. It not only assists researchers in grasping the current hotspots in this field but also reveals potential directions for future investigation. Moreover, future studies can optimize immunotherapy strategies based on hotspot predictions to decelerate the progression of atherosclerosis.

immunology
The Epidemiology of Antiphospholipid Syndrome: A Population‐Based Study

Ali Duarte‐García,Michael M. Pham,Cynthia S. Crowson,Shreyasee Amin,Kevin G. Moder,Rajiv K. Pruthi,Kenneth J. Warrington,Eric. L. Matteson

DOI: https://doi.org/10.1002/art.40901

2019-08-01

Abstract:OBJECTIVE: To estimate the annual incidence and prevalence of and frequency of mortality associated with antiphospholipid syndrome (APS).METHODS: An inception cohort of patients with incident APS in 2000-2015 from a geographically well-defined population was identified based on comprehensive individual medical records review. All cases met the 2006 Sydney criteria for APS (primary definition) or had a diagnosis of APS confirmed by physician consensus (secondary definition). Levels of lupus anticoagulant, IgM and IgG anticardiolipin antibodies, and anti-β2-glycoprotein I antibodies were tested in a centralized laboratory. Incidence rates were age- and sex-adjusted to the 2010 US white population. Prevalence estimates were obtained from the incidence rates, assuming that there was no increased mortality associated with APS and that migration in or out of the area was independent of disease status.RESULTS: Among this cohort in 2000-2015, 33 cases of incident APS, as defined by the Sydney criteria, were identified (mean age of patients 54.2 years; 55% female, 97% white). The annual incidence of APS in adults ages ≥18 years was 2.1 (95% confidence interval [95% CI] 1.4-2.8) per 100,000 population. Incidence rates were similar in both sexes. The estimated prevalence of APS was 50 (95% CI 42-58) per 100,000 population, and was similar in both sexes. Six patients (18%) had a concurrent diagnosis of systemic lupus erythematosus. The most frequent clinical manifestation was deep vein thrombosis. The overall frequency of mortality among patients with APS was not significantly different from that in the general population (standardized mortality ratio 1.61, 95% CI 0.74-3.05).CONCLUSION: APS occurred in ~2 persons per 100,000 population per year. The estimated prevalence was 50 per 100,000 population. Overall mortality was not notably different from that observed in the general population.

rheumatology
Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review

Jaume Alijotas-Reig,Enrique Esteve-Valverde,Ariadna Anunciación-Llunell,Joana Marques-Soares,Josep Pardos-Gea,Francesc Miró-Mur

DOI: https://doi.org/10.3390/jcm11030675

IF: 3.9

2022-01-28

Journal of Clinical Medicine

Abstract:Antiphospholipid syndrome is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity associated with persistent antiphospholipid antibody positivity. Cases fulfilling the Sydney criteria for obstetric morbidity with no previous thrombosis are known as obstetric antiphospholipid syndrome (OAPS). OAPS is the most identified cause of recurrent pregnancy loss and late-pregnancy morbidity related to placental injury. Cases with incomplete clinical or laboratory data are classified as obstetric morbidity APS (OMAPS) and non-criteria OAPS (NC-OAPS), respectively. Inflammatory and thrombotic mechanisms are involved in the pathophysiology of OAPS. Trophoblasts, endothelium, platelets and innate immune cells are key cellular players. Complement activation plays a crucial pathogenic role. Secondary placental thrombosis appears by clot formation in response to tissue factor activation. New risk assessment tools could improve the prediction of obstetric complication recurrences or thromboses. The standard-of-care treatment consists of low-dose aspirin and prophylactic low molecular weight heparin. In refractory cases, the addition of hydroxychloroquine, low-dose prednisone or IVIG improve pregnancy outcomes. Statins and eculizumab are currently being tested for treating selected OAPS women. Finally, we revisited recent insights and concerns about the pathophysiology, diagnosis and management of OAPS.

medicine, general & internal
Bibliometric analysis of the global trends in immune‐related recurrent pregnancy loss research over the last two decades

Jing‐wei Li,Honglin Xv,Ren‐tao Wan

DOI: https://doi.org/10.1111/jog.15907

2024-03-13

Journal of Obstetrics and Gynaecology Research

Abstract:Problem A comprehensive analysis was conducted to explore the scientific output on immune‐related recurrent pregnancy loss (RPL) and its key aspects. Despite the lack of clear explanations for most RPL cases, immune factors were found to play a significant role. Method of Study The study utilized a bibliometric approach, searching the Web of Science Core Collection database for relevant literature published between 2004 and 2023. Results The collected dataset consisted of 2228 articles and reviews, revealing a consistent increase in publications and citations over the past two decades. The analysis identified the United States and China as the most productive countries in terms of RPL research. Among the institutions, Fudan University in China emerged as the top contributor, followed by Shanghai Jiaotong University. Kwak‐kim J was the most prolific author, while Christiansen Ob had the highest number of co‐citations. The top 25 co‐cited references on diagnosis, treatment, and mechanisms formed the foundation of knowledge in this field. By examining keyword co‐occurrence and co‐citations, the study found that antiphospholipid syndrome and natural killer cells were the primary areas of focus in immune‐related RPL research. Additionally, three emerging hotspots were identified: chronic endometritis, inflammation, and decidual macrophages. These aspects demonstrated increasing interest and research activity within the field of immune‐related RPL. Conclusions Overall, this comprehensive bibliometric analysis provided valuable insights into the patterns, frontiers, and focal points of global scientific output related to immune‐related RPL.

obstetrics & gynecology
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

Jason S Knight,D Ware Branch,Thomas L Ortel

DOI: https://doi.org/10.1136/bmj-2021-069717

2023-02-27

BMJ

Abstract:Abstract Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by circulating autoantibodies that recognize cell surface phospholipids and phospholipid binding proteins. The result is an increased risk of thrombotic events, pregnancy morbidity, and various other autoimmune and inflammatory complications. Although antiphospholipid syndrome was first recognized in patients with lupus, the stand alone presentation of antiphospholipid syndrome is at least equally common. Overall, the diagnosis appears to affect at least one in 2000 people. Studies of antiphospholipid syndrome pathogenesis have long focused on logical candidates such as coagulation factors, endothelial cells, and platelets. Recent work has shed light on additional potential therapeutic targets within the innate immune system, including the complement system and neutrophil extracellular traps. Vitamin K antagonists remain the mainstay of treatment for most patients with thrombotic antiphospholipid syndrome and, based on current data, appear superior to the more targeted direct oral anticoagulants. The potential role of immunomodulatory treatments in antiphospholipid syndrome management is receiving increased attention. As for many systemic autoimmune diseases, the most important future direction is to more precisely identify mechanistic drivers of disease heterogeneity in pursuit of unlocking personalized and proactive treatments for patients.

medicine, general & internal
An advanced understanding of the heterogeneous clinical features of “non-criteria” obstetric antiphospholipid syndrome: Two case reports and a literature review

Xue Peng,Xi Tan,Aiyun Xing

DOI: https://doi.org/10.3389/fimmu.2023.1122127

IF: 7.3

2023-02-14

Frontiers in Immunology

Abstract:Antiphospholipid syndrome (APS) is an acquired autoimmune disorder characterized by recurrent venous and/or arterial thrombosis and/or pregnancy complications, in the presence of elevated antiphospholipid (aPL) antibodies. APS in pregnant women is referred to as “obstetrical” APS (OAPS). The diagnosis of definite OAPS requires the presence of one or more typical clinical criteria and persistent aPL antibodies at least 12 weeks apart. However, the classification criteria for OAPS have generated wide discussion, with a growing impression that certain patients not fully meeting these criteria might be inappropriately excluded from the classification, which is known as “non-criteria” OAPS. We present here two unique cases of potentially lethal “non-criteria” OAPS, complicating severe preeclampsia, fetal growth restriction (FGR), liver rupture, preterm birth, refractory recurrent miscarriages, or even stillbirth. We further share our diagnostic search and analysis, treatment adjustment, and prognosis for this unusual antenatal event. We will also present a short review of an advanced understanding of the pathogenetic mechanisms of this disease, heterogeneous clinical features, and potential significance.

immunology
"APS pregnancy - The offspring"

Viktoria Bitsadze,Cecilia Nalli,Jamilya Khizroeva,Daniele Lini,Laura Andreoli,Andrea Lojacono,Elisa Fazzi,Yehuda Shoenfeld,Angela Tincani,Alexander Makatsariya

DOI: https://doi.org/10.1177/0961203320947154

IF: 2.858

Lupus

Abstract:Background: Antiphospholipid antibody syndrome (APS) is an autoimmune disease that affects women in childbearing age. In recent years, great improvements were achieved in the management of pregnancies in these women. Prematurity could be an issue in these pregnancies, mainly due to the direct pathogenic effect of antiphospholipid antibodies (aPL) on the placental surface. Maternal IgG aPL can cross the placenta and theoretically interact with the growing fetus; it could reach the fetal brain because of the incompleteness of the fetal blood-brain barrier: whether this can have an effect on brain development is still debated. Neonatal thrombosis episodes have been described in children positive for aPL, not always associated with maternal antibody positivity, suggesting the hypothesis of a possible aPL de novo synthesis in fetus and neonates. Methods: A keyword-based literature search was conducted. We also described a case of neonatal catastrophic antiphospholipid syndrome (CAPS). Results: Offspring of patients with APS are generally healthy but the occurrence of neonatal thrombosis or minor neurological disorders were reported. Conclusions: The limited number of the available data on this sensitive issue supports the need for further studies. Clinical follow-up of children of mothers with APS seems to be important to exclude, in the neonatal period, the occurrence of aPL associated pathological events such as thrombosis, and in the long-term, impairment in learning skills or behavioral problems.
Progress in the field of animal models of antiphospholipid syndrome

Xinnan Gao,Dan Ma,Liangyu Mi,Jingwen Zhao,Qi An,Zhiying Guo,Baoqi Yang,Liyun Zhang,Ke Xu

DOI: https://doi.org/10.1080/08916934.2024.2391350

IF: 3.5

2024-08-20

Autoimmunity

Abstract:Antiphospholipid syndrome (APS) is an autoimmune disease characterized by recurrent arteriovenous thrombosis and pathological pregnancy, accompanied by persistent antiphospholipid antibodies, (aPL). The incidence of APS is increasing year by year, clinicians lack of understanding of this type of disease, easy to misdiagnose and miss the diagnosis. Therefore, it is extremely important to establish a suitable animal model to reduce the process of disease development as much as possible and improve clinicians' understanding and understanding. This review will summarize the animal models of APS from the aspects of modeling methods, modeling mechanism, evaluation indicators and advantages and disadvantages of methods, providing a reference for finding an animal model highly similar to human APS, helping researchers to further clarify the pathogenesis of APS and find potential therapeutic targets, so as to achieve early diagnosis, early intervention, and ultimately improve the prognosis of patients.

immunology
Bibliometrics and Visual Analysis of Adult-onset Still Disease (1976–2020)

Bowen Xu,Jian Wang,Xiaoying Meng,Binghao Bao

DOI: https://doi.org/10.3389/fpubh.2022.884780

IF: 5.2

2022-06-15

Frontiers in Public Health

Abstract:Background: Adult-onset Still Disease (AoSD) is a rare disorder without standardized diagnostic criteria. People are paying more and more attention to its research. At present, no published studies have assessed the AoSD field using bibliometric tools. This study aimed to analyze research hotspots and frontiers through bibliometrics to provide a scientific and accurate reference for new and existing researchers. Methods: Data were obtained from the Web of Science core database and analyzed by CiteSpace, VOSviewer, and Microsoft Excel. Results: Involving 86 countries and regions, a total of 11,121 authors published 2,199 articles in 676 journals. These studies were published from 1976 to 2020. The United States published the most related articles (397). The United States, France, Italy, and Germany were the top four countries with a high H-index. Authors and institutions with high number of published articles and high citations are mainly located in France and Italy. High-frequency keywords include classification, criteria, diagnosis, and therapy method. Keyword clustering covers the connection between AoSD and rheumatoid arthritis, disease diagnosis, classification, and risk factors. Conclusions: The research on AoSD focuses on the diagnosis and differential diagnosis of the disease. Targeted therapy will become a research hotspot in the future, and relevant clinical research needs to appropriately expand the sample size and improve the credibility of the conclusions. The data reported in this study can serve as a useful resource for researchers studying AoSD.

public, environmental & occupational health
Drugs to be used with caution in patients with asthma.

T. Craig

1996-09-01

American family physician

Abstract:
Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.

J. Varley,G. Mcgown,M. Thorncroft,M. Santibanez-Koref,A. Kelsey,K. Tricker,D. Evans,J. Birch

IF: 11.2

1997-08-01

Cancer Research

Abstract:We have previously reported on the analysis of TP53 coding mutations in 12 classic Li-Fraumeni syndrome (LFS) families plus 9 families that were Li-Fraumeni-like (LFL) families (J. M. Birch et al., Cancer Res., 54: 1298-1304, 1994). Mutations were found in 6 of 12 LFS families and in 1 of 9 LFL families. We have now extended these studies to include an additional nine LFS and nine LFL families, and TP53 mutations have been detected in eight of nine LFS families and in three of nine LFL families. Six of the new mutations described here are the same as those previously identified in other Li-Fraumeni families and are missense mutations at codons 245, 248, and 273 (in two families); a nonsense mutation at codon 209; and a mutation at the splice donor site in exon 4. The other five mutations are novel germ-line mutations and include missense mutations at codons 136 and 344, a 2-bp deletion within codon 191, a splice acceptor mutation in intron 3, and a 167-bp deletion of part of exon 1 and intron 1. In addition, we have detected a codon 175 mutation in a family previously reported as TP53 negative. To summarize all of the data from the families we have studied in this and our previous report (J. M. Birch et al., Cancer Res., 54: 1298-1304, 1994), mutations have been detected in 15 of 21 LFS families (71%) and in 4 of 18 LFL families (22%). These figures are somewhat higher than those previously reported by us and others for the frequency of TP53 mutations in LFS and LFL families. This could reflect our analysis of all 11 exons of TP53, including noncoding regions, as well as the use of direct sequencing rather than other less-sensitive mutation detection methods.
Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.

Timothy Heffron

DOI: https://doi.org/10.1021/ACS.JMEDCHEM.6B00618

IF: 8.039

2016-08-03

Journal of Medicinal Chemistry

Abstract:In addition to each of the factors that govern the identification of a successful oncology drug candidate, drug discovery aimed at treating neurological cancer must also consider the presence of the blood-brain barrier (BBB). The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small molecules from freely reaching the brain, where neurooncologic malignancies reside. Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable. This Perspective discusses the unmet need for neurooncology treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clinical inhibitors of kinases that are of interest for the treatment of brain cancer.

Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis.

Global research landscape on antiphospholipid syndrome and systemic lupus erythematosus: Trends, collaborations, and future directions

Research Progress on the Relationship between Anticardiolipin Antibodies and Adverse Pregnancy Outcomes

Antiphospholipid Syndrome: a Survey of Clinical Characters in Ten Cases

Hughes syndrome: The discovery of the antiphospholipid syndrome

Clinical analysis of the outcome in pregnant patients with Antiphospholipid syndrome

Nitroalcohol Induced Hydrogel Formation in Amine-Functionalized Polymers.

Bibliometric analysis of global literature productivity in systemic lupus erythematosus from 2013 to 2022

[Research Hotspots on Systemic Lupus Erythematosus in Pregnancy Based on Bibliometrics].

A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction

The Epidemiology of Antiphospholipid Syndrome: A Population‐Based Study

Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review

Bibliometric analysis of the global trends in immune‐related recurrent pregnancy loss research over the last two decades

Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

An advanced understanding of the heterogeneous clinical features of “non-criteria” obstetric antiphospholipid syndrome: Two case reports and a literature review

"APS pregnancy - The offspring"

Progress in the field of animal models of antiphospholipid syndrome

Bibliometrics and Visual Analysis of Adult-onset Still Disease (1976–2020)

Drugs to be used with caution in patients with asthma.

Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.

Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.